Leo Heyndríckx

Instituut voor Tropische Geneeskunde — Belgium

Immunology and Microbiology · Life Sciences

30h-index2.5kcitations99works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV Research and Treatment(61), HIV/AIDS drug development and treatment(27), SARS-CoV-2 and COVID-19 Research(26), COVID-19 Clinical Research Studies(14), Immune Cell Function and Interaction(14)

Publications98 total

Patterns and functional consequences of antibody speciation in maternal-fetal transfer of coronavirus-specific humoral immunity
PLoS Pathogens·2025Open Access
Celluloepidemiology—A paradigm for quantifying infectious disease dynamics on a population level
Science Advances·2025· 1 citedOpen Access
Patterns and functional consequences of antibody speciation in maternal-fetal transfer of coronavirus-specific humoral immunity
2024Open Access
Persistent defect in SARS-CoV-2 humoral and cellular immunity in lung transplant recipients
The Journal of Heart and Lung Transplantation·2024· 3 citedOpen Access
Hybrid Immunity Overcomes Defective Immune Response to COVID-19 Vaccination in Kidney Transplant Recipients
Kidney International Reports·2023· 3 citedOpen Access
SARS-CoV-2 vaccination elicits broad and potent antibody effector functions to variants of concern in vulnerable populations
Nature Communications·2023· 8 citedOpen Access
Third dose of COVID-19 mRNA vaccine closes the gap in immune response between naïve nursing home residents and healthy adults
Vaccine·2023· 4 citedOpen Access
Validation of a Reporter Cell Line for Flavivirus Inhibition Assays
Microbiology Spectrum·2023· 1 citedOpen Access
Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients
American Journal of Transplantation·2023· 27 citedOpen Access
Alternative sampling specimens for the molecular detection of mpox (formerly monkeypox) virus
Journal of Clinical Virology·2022· 35 citedOpen Access
Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial
PLOS Global Public Health·2022· 5 citedOpen Access
Younger Children Develop Higher Effector Antibody Responses to SARS-CoV-2 Infection
Open Forum Infectious Diseases·2022· 15 citedOpen Access
Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients
2022· 2 citedOpen Access
A High-Throughput Yellow Fever Neutralization Assay
Microbiology Spectrum·2022· 17 citedOpen Access
A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity
Molecular Therapy·2022· 54 citedOpen Access
Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant
npj Vaccines·2022· 49 citedOpen Access
Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients
Cancer Cell·2022· 26 citedOpen Access
Asymptomatic Monkeypox Virus Infections Among Male Sexual Health Clinic Attendees in Belgium
SSRN Electronic Journal·2022· 7 citedOpen Access
Three doses of the BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 B.1.1.529 (Omicron) variant of concern
2021· 8 citedOpen Access
A high-throughput neutralization assay for yellow fever serodiagnostics
2021Open Access
page 1 of 5Next →

Frequent Co-authors

Wouter Janssens(19), Kevin K. Ariën(19), Guido van der Groen(18), Johan Míchiels(15), Betty Willems(14), Katrien Fransen(13), Katleen Vereecken(13), Peter Piot(11), Isabelle Desombere(9), John N. Nkengasong(7), Arnaud Marchant(7), Guido Vanham(6), Pieter Pannus(6), Maria E. Goossens(6), Guido Vanham(6), Peter M. Ndumbe(5), J. Motte(5), Éric Delaporte(5), Stanislas Goriely(4), Sandra Coppens(4)